Model Organisms in Drug Discovery and Development: An Industry Analysis

TABLE OF CONTENTS

Chapter 1: Executive Summary

Scope of this Report

Summary of Findings in this Report

Market Segmentation of the Model Organisms Space: Why Model Organisms and Where Do They Fit in Drug Discovery and Development?

Model Organisms and the Various Disease Areas Where they are Currently Being Deployed

Overview of the Competitive Landscape

Opportunities in the Model Organisms Space and Direction of the Field

Chapter 2: Current and Emerging Model Organisms in Drug

Discovery and Development

Scope of this Chapter

Introduction

The Various Model Organisms Deployed in Drug Discovery and Development

Caenorhabditis elegans (C. elegans)

Zebra.sh (Danio rerio)

Diseases where Zebra.sh have had Impact as a Model System

Cancer Biology and Apoptosis

The Mouse (Mus musculus or Mus spretus)

The Rat

The Fruit Fly (Drosophila melanogaster)

Summary

Comparisons Across the Model Organisms Landscape: Current and Emerging Model Organisms

Relevant Scienti.c Literature References in the Model Organisms Space Cited in this Chapter

Chapter 3: Market Opportunity in the Model Organisms Space

Scope of this Chapter

Proprietary End-user Survey Administered by D&MD

Quantitative Market Parameters

Qualitative Factors Affecting the Model Organisms Marketplace

What technology and market trends in the model organisms space

Drug discovery and development segments in which animal models are

being deployed and are they growing or declining:

Key technologies used in conjunction with animal models

Novel and emerging animal models for pharmaceutical R&D:

Unmet needs in the pharmaceutical R&D space:

Current Technology and Market Trends in Model Organisms for Drug Discovery and

Development

Intellectual Property (Patent) Volume and Trends in the Model Organisms Space

Quantitative Market Modeling of the Model Organisms Space

Strategic Analysis and Trends in the Model Organisms Space

Chapter 4: Deploying Model Organisms in Drug Discovery and  Development Presentation

Chapter 5: Company Pro.les

AVEO Pharmaceuticals, Inc.

BioMarker Pharmaceuticals, Inc.

Cambria Biosciences

Chronogen

Danio Labs

Devgen

Discovery Genomics

Exelixis

ARTEMIS Pharmaceuticals GmbH

Ingenium Pharmaceuticals AG

Lexicon Genetics Inc.

Phenomix

Phylonix Pharmaceuticals, Inc.

Union Biometrica

Xenogen

Zygogen, LLC

TABLE OF EXHIBITS

Exhibit 1.1 Business Models in the Model Organisms Space

Exhibit 1.2 Various Model Organisms and the Disease Areas Where They Are Deployed Currently

Exhibit 1.3 Summary of the Competitive Landscape in the Model Organisms Space

Exhibit 2.1 Advantages of the Zebra.sh over the Mouse as a Model System to Study Human Diseases

Exhibit 2.2 Comparative Analysis of the Model Organisms Space (Features and Bene.ts)

Exhibit 3.1 Key Challenges in the Deployment of Model Organisms in Drug Discovery

Exhibit 3.2 The Top Drivers in the Model Organisms Marketplace

Exhibit 3.3 Total Screening in the Pharmaceutical Industry Performed Using Animal Models

Exhibit 3.4 Expectation of Growth/Decline in Cost Per Data Point Allocated to Model Organisms

Exhibit 3.5 The Market Landscape and its Expected Evolution in the Model Organisms Space

Exhibit 3.6 Model Organisms Patents Distributed by Year of Filing

Exhibit 3.7 Assignees of Model Organism Patents

Exhibit 3.8 Model Organism Patents Grouped by Assignee Country

Exhibit 3.9 Business Model of Companies in the Model Organisms Space

Exhibit 3.10 Adoption Curve: Model Organisms Marketplace with Time

Exhibit 3.11 No Clear Winner Yet in the Model Organisms Space: Market Opportunity Exists for New Entrants